Successful Treatment with Stapokibart in a Severe Uncontrolled CRSwNP Patient: A Case of Rapid Symptom Resolution After Biologic and Surgical Failures

Chronic rhinosinusitis with nasal polyps (CRSwNP), particularly the type 2 endotype driven by IL-4/IL-13, remains challenging in a subset of patients refractory to surgery, allergen immunotherapy (AIT), and existing biologics. This case report describes a 29-year-old male with severe, multirefractory CRSwNP who achieved rapid and sustained remission with stapokibart (CM310), a novel anti-IL-4Rα monoclonal antibody, after failing 2 endoscopic sinus surgeries, omalizumab, and AIT. Following a regimen of 300 mg every 2 weeks, the patient exhibited significant olfactory improvement within 1 week and near-complete anosmia resolution by week 4. At 32 weeks, marked reductions in polyp burden, symptom scores (22-item Sinonasal Outcome Test (SNOT-22), Visual Analogue Scale (VAS), nasal congestion score (NCS), total symptom score (TSS)), and serum total IgE were documented. This case highlights stapokibart as a potent therapeutic option capable of inducing significant clinical response where conventional interventions have failed, supporting further investigation into IL-4Rα blockade for treatment-refractory CRSwNP.